Multiplex Immunofluorescence (mIF): Analytical Validation for Vectra 9C (MD Anderson)
BRD ID: 3,109
Source: CIMAC-CIDC Network Tier: SOP Number of times downloaded: 134
Description
This assay analytical validation and performance report describes the methods used to validate the multiplex immunofluorescence (mIF) assay for analysis with the Vectra 9C panel (CD34, CD3, CD45RO, FOXP3, PD1, PD-L1, and CD68) in paraffin sections of bone marrow clots from acute myeloid leukemia patients. The document also presents data supporting the reported accuracy, precision, analytical sensitivity, range, as well as quality control procedures. It is used by a Cancer Immune Monitoring and Analysis Center (CIMAC) at the MD Anderson Cancer Center. It is a product of the CIMAC and Cancer Immunologic Data Center Network (CIMAC-CIDC Network; https://dctd.cancer.gov/ResearchNetworks/cimacs_cidc_network.htm), a Cancer Moonshot Initiative.
Documents for Download
Analytical report_mIF_Vectra9C_03.03.23_MDACC 508_Final rep.pdf [Size: 878 KB]Biospecimens
- Fluid - Bone Marrow
- Tissue - Tonsil
Diagnoses
- Normal
- Neoplastic - Leukemia
Topics
- Biospecimen Processing
- Platform-specific Methodology
Associated SOP Compendiums
- Biospecimen Processing
- Platform-specific Methodology